权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of a rapid diagnostic assay for Myasthenia Gravis

重症肌无力快速诊断检测方法的开发

基本信息

批准号：
9909271
负责人：
LANCE P FORD
金额：
$ 22.5万
依托单位：
ATTOGENE
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-30 至 2021-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9909271
关键词：
Algae Amputees Anatoxins Antibodies Autoantibodies Binding Biohazardous Substance Biological Assay Blurred vision Breathing Cell Line Cell membrane Cells Cholinergic Receptors Cholinesterase Inhibitors Clinical Cone Consumption Cyclic GMP Decision Making Deglutition Detection Development Devices Diagnosis Diagnostic tests Diplopia Disease Disease Progression Early Diagnosis Equipment Ethics Exposure to Eye Facial Expression Fc Receptor Food Safety Goals Gold Colloid Hazardous Substances Health Human Immunodominant Epitopes Immunosuppressive Agents Impairment Individual Industry Intravenous Immunoglobulins Label Laboratory Personnel Lateral Life Marines Medical Membrane Methodology Methods Monitor Motor Endplate Muscle Muscle Fatigue Muscle Weakness Muscle function Myasthenia Gravis Neurotoxins Nicotinic Receptors Pathologist Patients Penetration Peptides Performance Pharmaceutical Preparations Phase Physicians Physiological Plasmapheresis Preparation Price Production Property Quality of life Radioactive Rattus Reagent Rhabdomyosarcoma Sampling Savings Secure Sensitivity and Specificity Shortness of Breath Snails Snakes Source Speech Speed Symptoms Technology Test Result Testing Thymectomy Time Toxin Toxin Conjugates Translating Ventilator Visual anti-IgG associated symptom clinical Diagnosis commercial application common symptom cost diagnostic assay follow-up gymnodimine improved instrumentation limb amputation nanobodies novel phase 2 study prototype rapid detection receptor receptor binding screening treatment response user-friendly

项目摘要

Project Summary/Abstract The physiological effect of autoantibody binding to the motor endplate junction nicotinic acetylcholine receptors (AchR) causes numerous symptoms associated with Myasthenia Gravis (MG) and is characterized by drooping of one or both eyes, blurred or double vision, change in facial expression, difficulty swallowing, shortness of breath, impaired speech and weakness of muscle function. In some cases, a crisis can occur in which the muscles that control breathing weaken to the point where individuals require a ventilator. The disease can be treated by thymectomy, use of anticholinesterase medications, immunosuppressive drugs, plasmapheresis and intravenous immunoglobulin. Although this can be a life threatening and severely debilitating disease, MG clinical diagnosis often goes overlooked because muscles fatigue is a common symptom of many other disorders and most symptoms are not identified until there is a significant loss in AchR (∼30% of normal levels) thus earlier detection would be a clear advantage. The receptor binding assays for the detection of anti-AchR antibody found in the majority of MG patients are time consuming and typically rely on radioactively labeled toxin conjugate, expensive equipment and sophisticated detection technologies that require a highly skilled workforce. The objective of this proposal is to develop a novel lateral flow assay configuration for the rapid and sensitive detection of Anti-AchR. Our goal is to convert the radioactive anti-AchR receptor binding assays into a rapid, user-friendly and robust visual detection methodology. We expect that this assay will have significant commercial applications because it will be simple to perform, low cost, robust and is expected to be valuable for monitoring anti-AchR and possibly a large spectrum of other important compounds. The approach we propose will lead to significant cost and time saving improvements. This will enable broader testing throughout the medical industry and faster responses for treatment. These advantages would be a significant improvement for those diagnosed with MG.

项目总结/文摘